Mike Pellini

Background

Mike Pellini MD is a General Partner at S32 specializing in precision medicine and cancer technology investments. He previously served as CEO of Foundation Medicine (acquired by Roche in 2018) and President/COO of Clarient (acquired by GE Healthcare). He holds degrees from Boston College, Drexel University, and Jefferson Medical College. During COVID-19 he was a Senior Advisor to the Rockefeller Foundation's testing efforts. He serves on boards including Nusano, Octave BioSciences, TwinStrand Genomics, Exai Bio, and Delve Bio.

Investment Focus

Notable Investments

Thrive Earlier Detection

Multi-cancer early detection (acquired by Exact Sciences)

Octave BioSciences

Multiple sclerosis precision medicine platform

TwinStrand Genomics

Duplex sequencing for ultra-sensitive genomics